Acadia Pharmaceuticals Drug Fails in Late-Stage Schizophrenia Trial

Acadia Pharmaceuticals? treatment for Parkinson?s disease-related psychosis failed a Phase 3 trial that was studying use of the drug for schizophrenia patients who haven?t fully responded to existing therapies. The company announced the trial failure Monday after market close. Acadia (NASDAQ: ACAD) shares dropped about 4 percent on the news in after-hours trading, falling from [?]